Searchicon: search
Sort by
icon: arrow-right

News Releases

Merck Animal Health Presented New Data on NUMELVI® (atinvicitinib) Tablets for Dogs and MOMETAMAX ULTRA® (gentamicin, posaconazole, and mometasone furoate otic suspension) for Dogs at the 2025 European Veterinary Dermatology Congress

RAHWAY, N.J., September 12, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced new data demonstrating the safety and efficacy of NUMELVI® (atinvicitinib) Tablets for Dogs and MOMETAMAX ULTRA® (gentamicin, posaconazole, and mometasone furoate

icon: arrow-right

News Releases

Vets and Pet-Owners See Gaps in Flea and Tick Prevention, Highlighting Need for Year-Round Care, New Merck Animal Health Global Survey Finds

Data show pet owners face difficulties with consistent compliance, while veterinarians worry about inconsistent or incorrect medication administration In the U.S. Two-thirds of veterinarians note that most pet owners do not follow year-round treatment plan, despite evidence that fleas and tick are present during all seasons RAHWAY, N.J., August 19, 2025

icon: arrow-right

News Releases

Merck Animal Health Presents New Data Highlighting Commitment to the Development and Study of Parasite Prevention and Treatment for Dogs at the 2025 World Association for the Advancement of Veterinary Parasitology Congress 

Data to showcase depth and breadth of the BRAVECTO® (fluralaner) portfolio including the injectable and oral endectocide combination formulations RAHWAY, N.J., August 18, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced it will

icon: arrow-right

News Releases

European Commission Approves NUMELVI™ (atinvicitinib) Tablets for Dogs

NUMELVI from Merck Animal Health is the First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Treatment of Pruritus Associated with Allergic Dermatitis Including Atopic Dermatitis and Treatment of Clinical Manifestations of Atopic Dermatitis in Dogs RAHWAY, N.J., July 24, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United

icon: arrow-right

News Releases

Merck Animal Health Announces FDA Approval of EXZOLT™ (fluralaner oral solution) for Chickens, the First Systemic Treatment for Northern Fowl Mites

Innovative oral solution offers a safe and effective approach to combat northern fowl mite infestations in poultry RAHWAY, N.J., July 18, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and

icon: arrow-right

News Releases

FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health

RAHWAY, N.J., July 10, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and Drug

icon: arrow-right

Featured Stories

Big data can carry farming forward. Now more than ever, farmers must embrace it.

To most Americans, farmers remain unseen figures behind the food on their dinner tables — hand-written records, calloused hands, and long days of physical labor.

icon: arrow-right

News Releases

Merck Animal Health Receives Positive Opinion from CVMP for NOBIVAC®L6 and NOBIVAC® LoVo L6 Vaccines for Use in Dogs Against Leptospirosis

RAHWAY, N.J., June 12, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for the NOBIVAC® L6 and NOBIVAC®

icon: arrow-right

News Releases

Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs 

If Approved, NUMELVI Will Be the First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Treatment of Pruritus Associated with Allergic Dermatitis Including Atopic Dermatitis and Treatment of Clinical Manifestations of Atopic Dermatitis in Dogs RAHWAY, N.J., June 12, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States

icon: arrow-right

News Releases

Merck Animal Health Receives Positive CVMP Opinion for INNOVAX®-ND-IBD-ILT for Use in Chickens

RAHWAY, NJ, May 16, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced today announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for the INNOVAX®-ND-IBD-ILT vaccine.

icon: arrow-right

News Releases

Merck Animal Health and State of Kansas Announce $895 Million Investment in Manufacturing and Research & Development Facilities in De Soto

Merck Animal Health unveils its largest economic development project in recent history Rahway, NJ, May 8, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), and Kansas Governor Laura Kelly jointly announced today the $895

icon: arrow-right

News Releases

FDA Approves Merck Animal Health’s MOMETAMAX SINGLE™ to Treat Otitis Externa in Dogs

The leading manufacturer of otic treatments expands portfolio with the only FDA-approved, one dose, in-clinic treatment for Pseudomonas aeruginosa and other pathogens RAHWAY, N.J., May 02, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced

Previous 123456 Next